[Use of recombinant hematopoietic growth factors in autologous bone marrow transplantation and peripheral blood stem cell transplantation].
The number of bone marrow transplantation's in autologous settings is recently rising by 20% each year reflecting a great demand. Simultaneously new technics of autologous transplantation are being developed such as APBSCT, transplantation of stem cells after positive purging etc. This progress is very much dependent upon use of recombinant human hematopoietic growth factors (rHu-GF), mainly G-CSF, GM-CSF, erytropoetin and in experimental conditions IL-3, CSF and others. There are two main fields of application of rHu-GF: a) support of hematopoietic reconstitution after transplantation, and b) mobilisation of stem and progenitor cells from bone marrow to the peripheral blood with subsequent harvesting and PBSCT. The more experimental trials are focused on expansion ex vivo and in vivo as well as on bone marrow engineering procedures (positive purging etc). This paper summarises recent communications from 1993/4 and preliminary own observations illustrating a rising value of cytokine supported autotransplantation procedures.
Hołowiecki
J
J
Kliniki Hematologii Slaskiej A.M. w Katowicach.
D016026:Bone Marrow Transplantation / Q000379:methods*; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins; D033581:Stem Cell Transplantation
D016298:Hematopoietic Cell Growth Factors; D011994:Recombinant Proteins
Zastosowanie rekombinowanych hematopoetycznych czynników wzrostu w transplantacji szpiku i komórek macierzystych z krwi obwodowej.